33-104 : Drug Use-Results Survey of OPDIVO

33-104 : Drug Use-Results Survey of OPDIVO (Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2011230029

Enrollment

100

Registered

2023-08-04

Start date

2018-12-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chem

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy, who have recieved OPDIVO for the first time

Exclusion criteria

Exclusion criteria: Patients who have received OPDIVO previously

Design outcomes

Primary

Measure	Time frame
[Safety] a) Occurrence status of adverse drug reactions and infections, b) Factors that are considered to affect safety c) Adverse events	—

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-6-6222-5501

Outcome results